您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Encorafenib(LGX818)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Encorafenib(LGX818)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Encorafenib(LGX818)图片
CAS NO:1269440-17-6
规格:≥98%
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)540.01
FormulaC22H27ClFN7O4S
CAS No.1269440-17-6; 1269440-29-0 (R-isomer of LGX-818)
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 100 mg/mL (185.2 mM)
Water: <1 mg/mL
Ethanol: 100 mg/mL (185.2 mM)
SMILES CodeO=C(OC)N[C@@H](C)CNC1=NC=CC(C2=CN(C(C)C)N=C2C3=CC(Cl)=CC(NS(=O)(C)=O)=C3F)=N1
SynonymsLGX-818; Encorafenib; LGX818; LGX 818
实验参考方法
In Vitro

In vitro activity: Encorafenib (formerly known as LGX818) is a new-generation, highly potent, and orally bioavailable B-RAF(V600E) inhibitor with IC50 of 4 nM. It has little effect against wild-type BRAF. Encorafenib has selective anti-proliferative and apoptotic activity on cells expressing BRAFV600E. It shows no significant activity against a panel of 100 kinases and no suppression of cell growth with more than 400 cell lines expressing BRAFV600E. In human melanoma xenograft models, oral administration of Encorafenib shows strong decrease in phospho-MEK and induces tumor regression. Raf kinase is a serine/threonine enzyme in the RAFMAPK/ERK signaling pathway. By inhibiting the activation of the RAF/MAPK/ERK signaling pathway, encorafenib may result in a decrease in proliferation of tumor cells. In the A375 (BRAFV600E) human melanoma cell line LGX818 suppresses phospho-ERK (EC50 = 3 nM) leading to potent inhibition of proliferation (EC50 = 4 nM). No significant activity is observed against a panel of 100 kinases (IC50> 900 nM) and LGX818 does not inhibit proliferation of> 400 cell lines expressing wild-type BRAF. Contributing to the high potency of LGX818 is the extremely slow off-rate from BRAFV600E which is not observed with other RAF inhibitors. In biochemical assays the dissociation half-life is>24 hours which translated into sustained target inhibition in cells following drug wash-out.


Kinase Assay: The Raf kinase activity reaction is started by the addition of 10 μL per well of 2×ATP diluted in assay buffer. After 3 hours (bRaf(V600E)) or 1 hour (c-Raf), the reactions are stopped with the addition of 10 μL of stop reagent (60 mM EDTA). Phosphorylated product is measured using a rabbit anti-p-MEK antibody and the Alpha Screen IgG (ProteinA) detection Kit, by the addition of 30 μL to the well of a mixture of the antibody (1:2000 dilution) and detection beads (1:2000 dilution of both beads) in bead buffer (50 mM Tris, pH 7.5, 0.01% Tween20). The additions are carried out under dark conditions to protect the detection beads from light. A lid is placed on top of the plate and incubated for 1 hour at room temperature, then the luminescence is read on a PerkinElmer Envision instrument. The concentration of each compound for 50% inhibition (IC50) is calculated by non-linear regression using XL Fit data analysis software.


Cell Assay: A375 is a melanoma cell line that harbors the B-Raf V600E mutation. A375-luc cells engineered to express luciferase is plated to 384-well white clear bottom plates as 1,500 cells/50 μL/well in DMEM containing 10% FBS. Test compounds, dissolved in 100% DMSO at appropriate concentrations, are transferred to the cells by a robotic Pin Tool (100 mL). The cells are incubated for 2 days at 25°C, then 25 μL of BrightGloTM is added to each well and the plates are read by luminescence. The concentration of each compound for 50% inhibition (IC50) is calculated by non-linear regression using XL Fit data analysis software. wild type and V600E B-Raf.

In VivoLGX818 treatment at oral doses as low as 6 mg/kg resulted in strong (75%) and sustained (>24 hours) decrease in phospho-MEK, even following clearance of drug from circulation in single dose PK/PD studies in human melanoma xenograft models (BRAFV600E). LGX818 induces tumor regression in multiple BRAF mutant human tumor xenograft models grown in immune compromised mice and rats at doses as low as 1 mg/kg. Consistent with the in vitro data, LGX818 is inactive against BRAF wild-type tumors at doses up to 300 mg/kg bid, with good tolerability and linear increase in exposure. Efficacy is also achieved in a more disease-relevant spontaneous metastatic melanoma and a model of melanoma brain metastasis. LGX818 is a potent and selective RAF kinase inhibitor with unique biochemical properties that contribute to an excellent pharmacological profile.
Animal modelRats
Formulation & Dosage6 mg/kg; oral
References[1] Darrin D Stuart, et al. Cancer Res, 2012, 72(8 Supplement): 3790; [2] J Hematol Oncol. 2013 Apr 25;6:30
生物活性


Fig. 1. LGX818 suppresses the ERK/MAPK pathway, inhibits proliferation and induces cell cycle arrest in BRAFV600E melanoma cells. Cancer Lett. 2016 Jan 28;370(2):332-44.



Fig. 2. LGX818 downregulates CyclinD1 dependent of DYRK1B, but not GSK3β. Cancer Lett. 2016 Jan 28;370(2):332-44.


Fig. 3. Apoptosis is not involved in LGX818-mediated melanoma cell growth inhibition. Cancer Lett. 2016 Jan 28;370(2):332-44.


Fig. 4. LGX818 induces senescence in BRAFV600E melanoma cells.Cancer Lett. 2016 Jan 28;370(2):332-44.


Fig. 5. LGX818 enhances autophagic flux and induces autophagy via inhibition of the mTOR pathway in BRAFV600E melanoma cells. Cancer Lett. 2016 Jan 28;370(2):332-44.


Fig. 6. Autophagy is involved in LGX818-induced senescence in BRAFV600E melanoma cells. Cancer Lett. 2016 Jan 28;370(2):332-44.